Research

Hormonal

Real-world use of tirzepatide for obesity management without type 2 diabetes involves significantly slower dose escalation and lower adherence compared to clinical trial protocols, with most patients remaining on doses ≤10 mg and roughly half discontinuing treatment within six months.

In real-world practice, tirzepatide is often used at lower doses (≤10 mg) than in clinical trials, and about half of patients stop treatment within six months. If you are using it, expect that dose escalation may be slower than recommended, and persistence is a challenge. If you discontinue, switching to another GLP-1 agonist like semaglutide is a common next step.

GoodQualifiesHIGH confidence
Tirzepatide dose escalation in this real-world cohort was slower than in clinical trials... At the fifth prescription refill (n = 448), 91.1% were receiving tirzepatide doses of ≤10 mg... At 6 months, tirzepatide adherence was 55.5% and persistence was 54.2%.
Theresa Hunter et al. · Diabetes Obesity and Metabolism · 2025

Why this rating

Large retrospective cohort study (N=10,193) with real-world data, though observational and subject to coding limitations.

Source

Real‐world use of tirzepatide among individuals without evidence of type 2 diabetes: Results from the Veradigm® database

Theresa Hunter et al. · Diabetes Obesity and Metabolism · 2025

DOI 10.1111/dom.16330

cohort · n=10193Cited 6×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →